Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin-tazobactam versus meropenem for ceftriaxone-resistant Enterobacteriaceae bloodstream infection
MOH_2018-12-25_004857Phase 3Recruiting
- Sponsor
- Rabin Medical Center
- Start
- Dec 2018
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Cephalosporin-resistant Enterobacteriaceae infection (ESBL-E) and Bacteremia comparing Piperacillin-tazobactam with Meropenem (2 arms). Primary endpoints: Mortality and Clinical failure. Started Dec 2018; status: recruiting.
02
Drugs
piperacillin + tazobactammeropenem
03
Conditions
Cephalosporin-resistant Enterobacteriaceae infection (ESBL-E)Bacteremia
Beyond the preview
Go deeper on MOH_2018-12-25_004857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-25_004857.